-
-
-
-
-
-
-
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
-
-
-
-
-
-
-
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
-
-
-
-
-
-
-
FDA extends review timeline for Denali's Hunter syndrome treatment
-
-
-
-
-
-
-
Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome
-
-
-
-
-
-
-
Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
-
-
-
-
-
-
-
Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
-
-
-
-
-
-
-
Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
-
1,198,729 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

